Randomized, double‐blind, placebo‐controlled study of interferon‐γ 1b in Friedreich Ataxia

OBJECTIVE: In vitro, in vivo, and open‐label studies suggest that interferon gamma (IFN‐γ 1b) may improve clinical features in Friedreich Ataxia through an increase in frataxin levels. The present study evaluates the efficacy and safety of IFN‐γ 1b in the treatment of Friedreich Ataxia through a dou...

Descripción completa

Detalles Bibliográficos
Autores principales: Lynch, David R., Hauser, Lauren, McCormick, Ashley, Wells, McKenzie, Dong, Yi Na, McCormack, Shana, Schadt, Kim, Perlman, Susan, Subramony, Sub H., Mathews, Katherine D., Brocht, Alicia, Ball, Julie, Perdok, Renee, Grahn, Amy, Vescio, Tom, Sherman, Jeffrey W., Farmer, Jennifer M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6414489/
https://www.ncbi.nlm.nih.gov/pubmed/30911578
http://dx.doi.org/10.1002/acn3.731

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6414489/
https://www.ncbi.nlm.nih.gov/pubmed/30911578
http://dx.doi.org/10.1002/acn3.731

Ejemplares similares